Urine N-terminal pro-B-type natriuretic peptide and plasma proenkephalin are promising biomarkers for early diagnosis of cardiorenal syndrome type 1 in acute decompensated heart failure: a prospective, double-center, observational study in real-world

What Was Tested

This observational study looks at BNP (Nesiritide).

Logistic regression was used to determine the predictors of CRS-1.

The area under the receiver operating curves (ROCs) was calculated to assess the early diagnostic value of pNGAL, pPENK, and uNT-proBNP/uCr for CRS-1.

To evaluate the prognostic risk of factors for the 90-d outcomes of all ADHF patients, the Cox regression was performed and the cumulative risk curve was plotted.

Why It Was Studied

Patients with acute decompensated heart failure (ADHF) show cardiorenal syndrome type 1 (CRS-1) are more likely to have a poor outcome.

However, the current criteria often lead to delayed CRS-1 diagnosis.

Who Took Part

According to the abstract, 121 patients were involved.

The plasma NT-proBNP (pNT-proBNP), pPENK, and uNT-proBNP were measured in 121 ADHF patients on admission.

How the Study Was Run

The plasma neutrophil gelatinase-associated lipocalin (pNGAL) was chosen as the reference.

What Was Measured

Patients with acute decompensated heart failure (ADHF) show cardiorenal syndrome type 1 (CRS-1) are more likely to have a poor outcome.

Therefore, the researchers evaluated the predictive value of plasma proenkephalin (pPENK) and urine NT-proBNP (uNT-proBNP) for early diagnosis of CRS-1 and vulnerable-phase prognosis in ADHF patients.

Topics PubMed links to this paper include Biomarkers, Cardio-Renal Syndrome, Early Diagnosis, Enkephalins, Heart Failure, Natriuretic Peptide, Brain and Peptide Fragments.

Author keywords: Cardiorenal syndrome type 1, acute decompensated heart failure, prediction, proenkephalin and urine N-terminal pro-B-type natriuretic peptide.

What This Means in Plain Language

This is an observational study of BNP (Nesiritide) in 121 patients.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Renal failure), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.